The start-up developer of medical foods and supplements is conducting clinical trials on two candidates to stave off muscle loss in elderly people. The firm soon may begin development of therapeutic product candidates with a separate business unit.

The start-up developer of medical foods and supplements is conducting clinical trials on two candidates to stave off muscle loss in elderly people. The firm soon may begin development of therapeutic product candidates with a separate business unit.

Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first full day of the 2014 J.P. Morgan health care conference, including chats with the CEOs of Elcelyx Therapeutics and Arecor, news from Juno Therapeutics and Galena Biopharma, and more.

Start-up fundraising for Q3 2013 totaled $559.4 million, down from last quarter’s big rally ($907.2 million) but still up from the sluggish first quarter ($398.7 million). More than half of that money went to biopharma companies, a group which also received investments through alliances with equity provisions.